A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae
Ημερομηνία
2016Γλώσσα
en
Λέξη-κλειδί
Επιτομή
Objective To develop a score to predict mortality in patients with bloodstream infections (BSIs) due to carbapenemase-producing Enterobacteriaceae (CPE). Patients and Methods A multinational retrospective cohort study (INCREMENT project) was performed from January 1, 2004, through December 31, 2013. Patients with clinically relevant monomicrobial BSIs due to CPE were included and randomly assigned to either a derivation cohort (DC) or a validation cohort (VC). The variables were assessed on the day the susceptibility results were available, and the predictive score was developed using hierarchical logistic regression. The main outcome variable was 14-day all-cause mortality. The predictive ability of the model and scores were measured by calculating the area under the receiver operating characteristic curve. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were calculated for different cutoffs of the score. Results The DC and VC included 314 and 154 patients, respectively. The final logistic regression model of the DC included the following variables: severe sepsis or shock at presentation (5 points); Pitt score of 6 or more (4 points); Charlson comorbidity index of 2 or more (3 points); source of BSI other than urinary or biliary tract (3 points); inappropriate empirical therapy and inappropriate early targeted therapy (2 points). The score exhibited an area under the receiver operating characteristic curve of 0.80 (95% CI, 0.74-0.85) in the DC and 0.80 (95% CI, 0.73-0.88) in the VC. The results for 30-day all-cause mortality were similar. Conclusion A validated score predictive of early mortality in patients with BSIs due to CPE was developed. Trial Registration clinicaltrials.gov Identifier: NCT01 764490. © 2016 Mayo Foundation for Medical Education and Research
Collections
Related items
Showing items related by title, author, creator and subject.
-
Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study
Harris P.N.A., Pezzani M.D., Gutiérrez-Gutiérrez B., Viale P., Hsueh P.-R., Ruiz-Garbajosa P., Venditti M., Tumbarello M., Navarro-Francisco C., Calbo E., Akova M., Giamarellou H., Oliver A., Almirante B., Gasch O., Martínez-Martínez L., Schwaber M.J., Daikos G., Pitout J., Peña C., Hernández-Torres A., Doi Y., Pérez F., Tuon F.F., Tacconelli E., Carmeli Y., Bonomo R.A., Pascual Á., Paterson D.L., Rodríguez-Baño J., del Toro M.D., Gálvez J., Falcone M., Russo A., Karaiskos I., Trecarichi E.M., Losito A.R., García-Vázquez E., Gómez J., Roilides E., Iosifidis E., Pournaras S., Prim N., Navarro F., Mirelis B., Origüen J., Juan R.S., Fernández-Ruiz M., Almela M., de la Calle C., Martínez J.A., Morata L., Larrosa N., Puig-Asensio M., Bou G., Molina J., González V., Bermejo J., Rucci V., de Gopegui E.R., Marinescu C.I., Fariñas M.C., Cano M.E., Gozalo M., Paño-Pardo J.R., Mora-Rillo M., Gómez-Zorrilla S., Tubau F., Tsakris A., Zarkotou O., Antoniadou A., Poulakou G., Souli M., Lowman W., Virmani D., Torre-Cisneros J., Machuca I., Gracia-Ahufinger I., Azap Ö.K., Helvaci Ö., Sahin A.O., Cantón R., Pintado V., Bartoletti M., Giannella M., Peter S., Hamprecht A., Badia C., Xercavins M., Fontanals D., Jové E., ESGBIS/REIPI/INCREMENT Group (2017)We describe regional differences in therapy for bloodstream infection (BSI) caused by extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) or carbapenemase-producing Enterobacteriaceae (CPE). Patients (n = ... -
Ceftazidime-avibactam to treat life-threatening infections by carbapenem-resistant pathogens in critically ill mechanically ventilated patients
Tsolaki V., Mantzarlis K., Mpakalis A., Malli E., Tsimpoukas F., Tsirogianni A., Papagiannitsis C., Zygoulis P., Papadonta M.-E., Petinaki E., Makris D., Zakynthinos E. (2020)Data on the effectiveness of ceftazidime-avibactam (CAZ-AVI) in critically ill, mechanically ventilated patients are limited. The present retrospective observational cohort study, which was conducted in two general intensive ... -
Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: Experience from a national registry study
Karaiskos I., ikaraiskos@hygeia.gr, Daikos G.L., Gkoufa A., Adamis G., Stefos A., Symbardi S., Chrysos G., Filiou E., Basoulis D., Mouloudi E., Galani L., Akinosoglou K., Arvaniti K., Masgala A., Petraki M., Papadimitriou E., Galani I., Poulakou G., Routsi C., Giamarellou H. (2021)Background: Infections caused by KPC-producing Klebsiella pneumoniae (Kp) are associated with high mortality. Therefore, new treatment options are urgently required. Objectives: To assess the outcomes and predictors of ...